Introduction
============

The term stereotactic body radiosurgery (SBRS) implies the delivery of a focused single dose of radiation therapy ([@b1-ol-05-06-1889]). This technique has been used in the treatment of various types of cancer in different anatomic sites, including primary or metastatic lung tumors ([@b2-ol-05-06-1889]--[@b4-ol-05-06-1889]), primary or secondary liver tumors ([@b5-ol-05-06-1889]--[@b7-ol-05-06-1889]), pancreatic tumors ([@b8-ol-05-06-1889]), gynecological cancer recurrences ([@b9-ol-05-06-1889]) and bone metastases ([@b10-ol-05-06-1889]).

With the delivery of a very high dose single fraction of radiation therapy, SBRS requires steep dose gradients, usually obtained by dynamic techniques or non-coplanar fixed fields. SBRS also requires high precision in the treatment delivery process. Therefore, it requires a short fraction length to reduce the risk of intra-fraction set-up deviations or organ motion.

Volumetric modulated arc therapy (VMAT) is a novel radiotherapy technique. VMAT differs both from standard intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiotherapy (3D-CRT), which operate in static conditions, and is characterized by dose delivery by dynamic arcs ([@b11-ol-05-06-1889]). During VMAT, the delivery of radiation occurs with a rotational movement of the linear accelerator (LINAC) gantry while a continuous variation of the beam's profile and intensity is obtained. VMAT requires a sophisticated technique for complex treatment planning. As VMAT has evolved from IMAT, VMAT has the advantage of high-dose conformity and improved sparing of healthy tissues. Therefore, VMAT may be theoretically useful for dose escalation and improved tumor control probability. In addition, the duration of dose delivery is very short, allowing the advantages of IMRT (high conformity index) to be combined in a reduced treatment time. The consequences are represented by a higher operating efficiency of each treatment unit, enhanced patient comfort and reduced risk of intrafraction deviations both in terms of set-up errors or organ motion.

For these reasons, VMAT is a potentially ideal technique for SBRS. However, it is not yet clear whether administration of very high doses in single fraction delivery with such a complex technique is possible. Additionally, the true capacity of VMAT to respect dose-volume constraints even in the case of high doses per fraction is uncertain. To the best of our knowledge, no data on VMAT-SBRS have been published.

Based on this background, a feasibility study regarding SBRS based on the VMAT technique (DESTROY-2 protocol) has been planned. The purpose of this analysis is to report the preliminary results of this study.

Materials and methods
=====================

Study characteristics
---------------------

This trial was conceived as a prospective dose escalation study. All patients consecutively observed at our Radiotherapy Unit (Catholic University, Campobasso, Italy) and matching the inclusion criteria were enrolled. The trial was approved by the Catholic University Institutional Review Board. A preliminary evaluation of technical feasibility was planned following the enrollment of the first 20 patients. Written informed patient consent was obtained from the patients.

Study objectives
----------------

The primary study end point was the definition of maximum tolerated dose (MTD) of SBRS with VMAT. The secondary objectives of the study were: i) feasibility evaluation in terms of dose-volume constraints; ii) analysis of the correlation between dosimetric and toxicity data; iii) analysis of the clinical response and iv) evaluation of local control.

Radiosurgery dose escalation
----------------------------

Each enrolled subject was included in a study arm according to the tumor site and disease stage, as demonstrated in [Table I](#t1-ol-05-06-1889){ref-type="table"}. Patients were sequentially assigned to a specific dose level as detailed in [Table II](#t2-ol-05-06-1889){ref-type="table"}. VMAT dose escalation was based primarily on the acute and subacute toxicity, as late toxicity is capable of occurring months or years later. Acute-subacute toxicities were defined as those that occurred within 6 months of receiving treatment. Toxicities registered ≥6 months post-radiation were defined as late toxicities. Dose-limiting toxicities (DLTs) were defined as any treatment-related non hematological adverse effects rated as ≥grade 3 or any hematological toxicity rated as ≥grade 4, by the National Cancer Institute Common Terminology Criteria for Adverse Events v.4.03 ([@b12-ol-05-06-1889]). If the DLT was not observed in the three patients at a given dose level, the trial proceeded to the next dose level, provided that 6 months of follow-up had occurred following the VMAT for the third patient of the cohort. If a DLT occurred in one of the three patients at a given dose level, treatment of up to three additional patients at this dose level was required. If the DLT occurred in more than one patient of the three patients' cohort, dose escalation was halted, and the dose level below that was considered to be the MTD. If a DLT occurred in two or more patients of the expanded six-patient cohort, dose escalation was terminated, and the dose level below that was considered to be the MTD. If a DLT occurred in less than two patients of the expanded six-patient cohort, the trial proceeded to the subsequent dose level. Different total VMAT doses were selected on initiation of the study as the highest dose levels to be evaluated, and were dependent on the study arm. Late toxicities were continuously monitored regardless of whether patients had documented disease progression.

Inclusion criteria
------------------

The following inclusion criteria were used: histological diagnosis of solid tumor (with the exception of germinal tumors) with the site and tumor stage as demonstrated in [Table I](#t1-ol-05-06-1889){ref-type="table"}; age, \>18 years; ECOG performance status, 0--3; adequate bone marrow function, which included neutrophil count, \>1500 *μ*l; platelets, \>100,000/ml; hemoglobin, \>9 g/dl. Additionally, for patients receiving irradiation to the kidney (lumbar/abdominal area) the inclusion criterion was creatinine, \<1.8 mg/dl; while the criteria for patients receiving irradiation to the liver were total bilirubin, \<3 mg/dl; lactate dehydrogenase, \<3-fold the normal value; aspartate aminotransferase, \<3-fold the normal value; alanine aminotransferase, \<3-fold the normal value and alkaline phosphatase, \<3-fold the normal value. Previous treatment with surgery and/or chemotherapy and/or radiotherapy was permitted.

Exclusion criteria
------------------

The following exclusion criteria were employed: ECOG, \>3; the presence of medical conditions which contraindicate radiation therapy, such as connective system disorders, severe uncompensated heart disease (in case of heart irradiation), acute diverticulitis, ulcerative colitis and pelvic inflammatory disease (in case of irradiation of the pelvis); comorbidities that in the opinion of the referring physician may constitute a risk to clinical trial participation.

End points and statistical analysis
-----------------------------------

Toxicity was evaluated by the Common Toxicity Criteria for Adverse Events (CTCAE) scale, version 4.03 ([@b12-ol-05-06-1889]). The presence of focal liver reaction was evaluated as outlined by Herfarth *et al*([@b13-ol-05-06-1889]). The survival curves were calculated with the Kaplan-Meier method ([@b14-ol-05-06-1889]). Statistical analysis was performed using SYSTAT software, version 11.0 (SPSS, Inc.; Chicago, IL, USA).

Patient set-up
--------------

Patient immobilization was performed with a stereotactic body frame (SBF; Elekta; Crawley, UK), which is an immobilization device used to define a stereotactic system of coordinates for the target position as opposed to anatomical landmarks such as bony structures or skin markers. This device was described in detail by Lax *et al*([@b15-ol-05-06-1889]) and clinical results have been published by Blomgren *et al*([@b16-ol-05-06-1889]). The SBF is a U-shaped rigid plastic frame, within which different sized vacuum pillows allow a reproducible immobilization for the repositioning of each patient. Patient repositioning is supported by a laser system directly attached to the body frame at defined longitudinal positions. Alignment of the stereotactic coordinate system of the SBF to the isocenter of the computed tomography (CT) machine or the treatment unit is performed by a stereotactic arc with scales in the anterior-posterior and lateral directions. The longitudinal stereotactic coordinate is found on a scale along the body frame sidewalls and is simply read on each CT-slice using a system of straight and oblique copper pieces, which function as fiducials. Moreover, to reduce the respiration mobility of targets close to the diaphragm, a compressor, attached to the SBF by a rigid arc, may be mechanically pressed into the patient's epigastrium to decrease the respiration motion.

CT simulation
-------------

To evaluate the reproducibility of the set-up, three CT scan evaluations were performed on three different days, with the aim of verifying that the set-up deviation was \<3 mm. In order to evaluate the organ motion produced by the respiratory movements, target displacement was measured. During free breathing, 30 axial CT scans were performed on the same slice. In the case of a displacement \>5 mm, the abdominal compressor of the SBF was applied and the CT scan for organ motion assessment was repeated. The final CT simulation, for the acquisition of axial images necessary for stereotactic localization and plan calculations, was produced with a spiral technique. Subsequently, 3-mm scans were acquired with a 3-mm interval between scans in the target region. For the remainder of the SBF, 10-mm slices were acquired and the interval between scans was 10 mm. In treating abdominal or pelvic targets, patients received 2 cc of oral Gastrografin, diluted in 0.5 l of water 30 min prior to CT scan acquisition. In case of mediastinal, abdominal or pelvic target volumes, intravenous infusion of an iodinated contrast medium was also used.

Volumes of interest
-------------------

The clinical target volume (CTV) was defined as the gross tumor volume (GTV) in case of metastases and primary lung tumors. A 5-mm margin was added to the GTV to define the CTV in primary tumors of the liver. The planning target volume (PTV) was individually defined for each patient based on the internal margin (IM) and the set-up margin (SM) assessment. The IM was defined based on respiratory excursions in 3D. The SM was set at 3 mm according to the ROSEL study ([@b17-ol-05-06-1889]). The OARs considered included: i) The thorax: the spinal cord, lungs, esophagus, heart, brachial plexus, peripheral nerves, large vessels, trachea and ribs; ii) The abdomen: the spinal cord, liver, stomach, small bowel, colon and kidneys; iii) The pelvis: the sacral plexus, small bowel, colon, rectum, anal canal, bladder, femoral heads and penile bulb.

Prescription
------------

A uniform method for the selection of the prescription isodose surface (IDS) was adopted. According to the ROSEL study ([@b17-ol-05-06-1889]), for each plan the IDS was selected as the greatest IDS fulfilling the two following criteria: 95% of the PTV volume reached 100% of the prescription dose and 99% of the PTV reached ≥90% of the prescription dose. The aim was to increase the dose heterogeneity so as to intensify the dose within the GTV. The maximum dose within the PTV should not exceed 140% of the prescribed dose. Careful attention was paid to ensure the maximum dose always remained within the GTV.

Treatment planning
------------------

VMAT plans were generated using the ERGO^++^ treatment planning system (TPS), version 1.7.3 (Elekta). This is an anatomy-based TPS that supplies a simplified approach to creating VMAT plans, by predefining a series of aperture shapes using Boolean operations in conjunction with the beam's eye view of the target and OARs. In the current study, all plans were generated with a single-arc rotation except for patient number 16, who was treated for two liver lesions and therefore required two arcs. The dose calculation was performed using the pencil beam algorithm with inhomogeneity correction and a dose grid resolution of 2 mm. VMAT plans were exported to the record and verify (R&V) system Mosaiq v. 1.6 (Impac Software; Elekta) by DICOM-RT for later irradiation. [Table III](#t3-ol-05-06-1889){ref-type="table"} lists the dose-volume constraints used ([@b5-ol-05-06-1889],[@b18-ol-05-06-1889],[@b19-ol-05-06-1889]).

Quality assurance
-----------------

Set-up deviation and organ motion assessments were performed as previously described. For quality assurance through treatment planning and delivery, two independent checks (IC1 and 2) were performed by medical and physics staff, as previously described ([@b20-ol-05-06-1889]).

Supportive therapy
------------------

Supportive therapy was prescribed according to the irradiated site. In the case of irradiation of two anatomic sites, such as the chest and the abdomen, supportive care was provided for both sites. In patients receiving irradiation to the chest, prescriptions included betamethasone 0.5 mg orally, 3 times daily for 1 month, followed by a gradual reduction, associated with gastric protection (H2-inhibitors). Patients receiving abdominal irradiation were prescribed metoclopramide 10 mg orally, 3 times a day, for ≤1 week following radiation therapy and rabeprazole 40 mg orally, once daily for 12 months (in case of irradiation of the stomach and/or the duodenum only). In addition, patients receiving irradiation to the upper abdomen were prescribed dexamethasone 12 mg intravenously (IV) 1 fl immediately prior to radiosurgery and 6 h after treatment, while 3 mg granisetron was administered immediately prior to radiosurgery by IV slow infusion.

Evaluation of response and follow-up
------------------------------------

The tumor response assessment was performed 8--12 weeks after treatment. Morphological imaging modalities were employed (CT with contrast medium and/or MRI with or without contrast) in all patients. Using this method, the tumor response was based on the response evaluation criteria in solid tumors (RECIST) criteria ([@b21-ol-05-06-1889]). If feasible, the response was also assessed with functional imaging, which included (^18^F)-fluorodeoxyglucose (FDG)-PET or choline PET for prostate cancer. In this study, the European Organisation for Research and Treatment of Cancer (EORTC) criteria were used ([@b22-ol-05-06-1889]). Specifically, the PET-based response was assessed according to criteria including progressive metabolic disease (PMD), stable metabolic disease (SMD), a partial metabolic response (PMR) and a complete metabolic response (CMR). PMD involved an increase in the tumor (^18^F)-FDG standardized uptake value (SUV) of \>25% within the tumor region defined on the baseline scan, a visible increase in the extent of tumor (^18^F)-FDG uptake of \>20% in the longest dimension, or the appearance of novel tumor (^18^F)-FDG uptake in metastatic lesions. SMD comprised an increase in the tumor (^18^F)-FDG SUV of \<25% or a decrease of \<15%, and no visible increase in the extent of the (^18^F)-FDG tumor uptake (i.e., not \>20% in the longest dimension). A partial metabolic response required a reduction of \>25% in the tumor (^18^F)-FDG SUV. A reduction in the extent of the tumor (^18^F)-FDG uptake was not a pre-requesite for a PMR, whereas a CMR negated a complete resolution of the (^18^F)-FDG uptake within the tumor volume, in order that it was indistinguishable from the surrounding normal tissue. The follow-up was performed according to the scheme detailed in [Table IV](#t4-ol-05-06-1889){ref-type="table"}.

Quality of life (QoL) evaluation
--------------------------------

The cancer linear analog scale (CLAS) score was used to evaluate the impact of SBRS on the patient's quality of life (CLAS1), energy level (CLAS2) and ability to undertake daily activities (CLAS3), both prior to and 3--4 weeks after radiotherapy. Patients scored their perceptions of these symptoms by placing a mark on a 100-mm line ([@b23-ol-05-06-1889]).

Results
=======

Patient characteristics
-----------------------

The preliminary analysis was based on the first 20 enrolled patients who had a total of 25 lesions ([Table V](#t5-ol-05-06-1889){ref-type="table"}). The median PTV size was 37.8 cc (range, 0.9--202.4). The prescribed dose ranged from 12--26 Gy to the PTV ([Fig.1](#f1-ol-05-06-1889){ref-type="fig"}).

Technical issues
----------------

The dose-volume constraints for OARs were observed in all patients using a single-arc technique. Only one patient, who was treated for two liver lesions, required a two-arc technique. To administer the prescribed doses, 1401.9--3246.2 monitor units (median, 2157.75) were employed with a median beam-on time of 6 min and 6 sec (range, 4 min and 0 sec to 9 min and 13 sec). In all patients, the treatment was performed without interruption or any other technical issues.

Acute toxicity and response
---------------------------

All patients were evaluable for acute toxicity. Twenty per cent of patients experienced grade 1 acute toxicity. No patients demonstrated acute toxicity \> grade 1. Twenty five lesions were evaluable for clinical response by morphological imaging. In the irradiated site, the tumor responses included 7 lesions with a complete response (CR; 28%), 5 with a partial response (PR; 20%) and 13 with stable disease (SD; 52%). Moreover, 18 lesions were evaluable for a clinical response by functional imaging as follows: 9 lesions with a CR (50%), 7 with a PR (39%) and 2 with SD (11%) ([Fig. 2](#f2-ol-05-06-1889){ref-type="fig"}). No difference in the CLAS score was observed prior to SBRS compared with at the first follow-up (data not shown).

Late toxicity and outcome
-------------------------

With a median follow-up time of 12 months (range, 8--20), no patients presented with late toxicity. Overall, 3 patients experienced local disease progression. One-year actuarial progression-free survival in the irradiated site was 88%, while 13 patients (65%) demonstrated progressive disease in sites different from the irradiated one.

Discussion
==========

We describe our initial experience with radiosurgery by VMAT. Large radiation doses were delivered to the 20 patients in this study, and the constraints of the OARs were observed and a simple single-arc technique was implemented (in 19/20 patients) in \<10 min. Acute toxicity was exclusively grade 1 (CTCAE 4.03). Considering the 25 lesions, a morphological response rate of 48% (95% CI, 24.2--70.2) and a functional response rate of 89% (95% CI, 58.6--98.7) were demonstrated.

There are few studies in the literature regarding the use of stereotactic VMAT. The majority of these are dosimetric studies concerned with spine ([@b24-ol-05-06-1889],[@b25-ol-05-06-1889]), lung ([@b24-ol-05-06-1889],[@b26-ol-05-06-1889]--[@b28-ol-05-06-1889]), brain ([@b29-ol-05-06-1889],[@b30-ol-05-06-1889]) and adrenal metastases ([@b31-ol-05-06-1889]). All of these studies have demonstrated an increased efficiency of VMAT in terms of treatment time, with respect to 3D-conformal or IMRT techniques. A number of these have also described improved conformity compared with 3D techniques ([@b26-ol-05-06-1889]--[@b28-ol-05-06-1889]) and a similar ([@b30-ol-05-06-1889]) or higher ([@b27-ol-05-06-1889],[@b28-ol-05-06-1889]) conformity compared with standard IMRT techniques. Clinical studies are less numerous and are concerned with the spine ([@b32-ol-05-06-1889]--[@b34-ol-05-06-1889]), arteriovenous malformations ([@b35-ol-05-06-1889]) and abdominal targets ([@b36-ol-05-06-1889]). These preliminary studies have mainly documented the technical feasibility of stereotactic VMAT, and all the authors have employed this technique in fractionated treatments. To the best of our knowledge, the present series represents the first clinical study on radiosurgery using VMAT.

In terms of feasibility, we stress that the dose-volume constraints were met in all patients in the current study. The use of relatively small doses, in this first phase of the study, likely facilitated this result. In addition, the use of high doses was tolerated at least in terms of acute toxicity. Moreover, the analysis of QoL- and fatigue-related indicators prior to and following radiosurgery demonstrated that SBRS was not associated with any detrimental effects. The low number of patients and the short follow-up time mean that is is not possible to assess the local control and late toxicity. However, the high index of an immediate response, particularly if assessed with functional imaging, and the absence of relevant toxicity should be noted.

From a practical perspective, introducing VMAT for radio-surgery resulted in a marked reduction in the treatment time. In our previous experience with stereotactic radiation therapy based on non-coplanar fixed fields, a time of 45 min was reserved for each treatment. In the present study concerning VMAT, a machine time of only 20 min per treatment was reserved. Considering the promising results in terms of the feasibility and the preliminary clinical results, the study should continue with the recruitment of additional patients to the subsequent dose levels.

![Example of dose distribution.](OL-05-06-1889-g00){#f1-ol-05-06-1889}

![Single liver metastasis: Fluorodeoxyglucose (FDG)-positron emission tomography (PET) before (A) and after (B) radiosurgery (26 Gy).](OL-05-06-1889-g01){#f2-ol-05-06-1889}

###### 

Inclusion criteria.

  Study arm                                                                                 Criteria
  ----------------------------------------------------------------------------------------- ------------------------------------------------------------------
  Lung                                                                                      Primary or secondary lung tumors
  Number of lesions: 1--5                                                                   
  Largest diameter \<5 cm                                                                   
  Surgical treatment not indicated                                                          
  No prior RT at the same site                                                              
  No chemotherapy 14 days before and after SBRS                                             
  Absence of bronchopulmonary                                                               
  Infections in active phase                                                                
  Liver                                                                                     Primary or secondary liver tumors
  Number of lesions ≤3 (four if two lesions \<3 cm and close together)                      
  Largest diameter \<6 cm (5 cm for 1 lesion, 4 cm for 2 lesions, and 3 cm for 3 lesions)   
  Distance \>6 mm from the gastrointestinal tract                                           
  Surgical treatment not indicated                                                          
  No previous RT to the liver                                                               
  No chemotherapy 14 days before and after SBRS                                             
  Absence of active liver infections                                                        
  Bone                                                                                      Bone metastases
  Number of lesions: 1--5                                                                   
  Largest diameter of the single lesion \<6 cm                                              
  Other                                                                                     Advanced primary tumor or local recurrence or distant metastasis
  Surgical treatment not indicated                                                          
  Excluded from other arms of the study                                                     

RT, radiotherapy; SBRS, stereotactic body radiosurgery.

###### 

Dose levels (Gy) planned and reached (underlined) in the different arms of the study.

  Level   Lung        Liver       Bone        Advanced
  ------- ----------- ----------- ----------- -----------
  1       [26]{.ul}   [26]{.ul}   12          16
  2       28          28          14          [18]{.ul}
  3       30          30          [16]{.ul}   20
  4       32          32          18          22
  5       34                      20          24
  6                               22          
  7                               24          

###### 

Dose-volume constraints.

  Organ                         Dose (Gy) or volume (% or cc)     Reference
  ----------------------------- --------------------------------- -------------------------------------------
  Ribs                          Dmax=30                           NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Heart/pericardium             Dmax=22                           NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Skin                          Dmax=26                           NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Esophagus                     Dmax=15.4                         NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Liver                         V~12Gy~ \<30%                     
                                V~7Gy~ \<50%                      Herfarth KK, 2001 ([@b5-ol-05-06-1889])
  Great vessels (mediastinum)   Dmax=37                           NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Bowel (small bowel/colon)     Dmax=12                           Herfarth KK, 2001 ([@b5-ol-05-06-1889])
  Spinal cord                   Dmax=14                           NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Brachial plexus               Dmax=17.5                         NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Sacral plexus                 Dmax=18                           Timmerman RD, 2008 ([@b19-ol-05-06-1889])
  Lungs                         V~7.4Gy~=1000 cc                  Timmerman RD, 2008 ([@b19-ol-05-06-1889])
  Kidneys                       V~8.4Gy~=800 cc (cortical area)   
                                V~10.6Gy~=2/3 volume (ilo)        Timmerman RD, 2008 ([@b19-ol-05-06-1889])
  Stomach                       Dmax=12.4                         NCCN v.2.2010 ([@b18-ol-05-06-1889])
  Trachea/large bronchus        Dmax=20.2                         NCCN v.2.2010 ([@b18-ol-05-06-1889])

NCCN, National Comprehensive Cancer Network.

###### 

Follow-up.

  Study arm   First follow-up                                 Subsequent follow-up
  ----------- ----------------------------------------------- ------------------------------------------------------------------------------------------------------
  Lung                                                        Chest CT and PET-CT at 3 months and every 6 months thereafter
  Liver       2 weeks after SBRS to evaluate acute toxicity   Abdominal CT and PET-CT at 3 months and every 6 months thereafter; focal hepatic reaction evaluation
  Bone                                                        Bone CT and PET-CT or bone-scan at 3 months and every 6 months thereafter (anticipated if symptoms)
  Advanced                                                    Body CT and PET-CT at 3 months and every 6 months thereafter (anticipated if symptoms)

SBRS, stereotactic body radiosurgery; CT, computed tomography; PET, positron emission tomography.

###### 

Patients characteristics and results.

  Patient   Gender   Age (years)   Study arm   Tumor                                  PTV (cc)   Prescribed dose (Gy)   Acute toxicity (CTCAE 4.03)        PET response                                        CT or MRI response   Local failure (0, no; 1, yes)   Local failure (months)
  --------- -------- ------------- ----------- -------------------------------------- ---------- ---------------------- ---------------------------------- --------------------------------------------------- -------------------- ------------------------------- ------------------------
  1         F        47            Bone        Breast: bone metastasis                6.2        12                     0                                                                                      NC                   0                               16
                                               Breast: bone metastasis                11.7       12                     0                                                                                      NC                   0                               16
  2         M        65            Liver       Nasopharynx: single liver metastasis   85.4       26                     Skin hyper-pigmentation G1         CR                                                  CR                   0                               15
  3         M        82            Advanced    Prostate: pelvic nodal metastasis      137.5      16                     0                                  CR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   CR                   0                               13
                                               Prostate pelvic nodal metastasis       133.8      16                     0                                  PR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   PR                   1                               13
  4         M        59            Bone        Prostate: bone metastasis              8.1        12                     0                                  CR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   CR                   0                               13
  5         F        81            Advanced    Vagina: nodule on the right wall       75.1       16                     Vaginal inflammation and pain G1   PR                                                  NC                   1                               8
  6         F        64            Lung        Colon: single lung metastasis          22.3       26                     0                                                                                      NC                   0                               8
  7         M        67            Bone        Prostate: bone metastasis              0.9        14                     0                                  CR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   NC                   0                               12
  8         M        72            Bone        Prostate: bone metastasis              8.4        14                     0                                  CR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   NC                   0                               6
  9         M        82            Advanced    Prostate: pelvic nodal metastasis      37.8       16                     0                                  NC[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   NC                   0                               8
                                               Prostate: pelvic nodal metastasis      12.5       16                     0                                  CR[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   CR                   0                               8
  10        F        63            Lung        Cervix: single lung metastasis         6.3        26                     Pneumonitis G1, esophagitis G1     PR                                                  NC                   0                               4
  11        F        63            Lung        Colon: single lung metastasis          50.9       26                     esophagitis G1                     CR                                                  CR                   0                               8
  12        M        66            Bone        Prostate: bone metastasis              10.2       14                     0                                  NC[^a^](#tfn4-ol-05-06-1889){ref-type="table-fn"}   NC                   0                               9
  13        F        70            Advanced    Breast: liver metastasis               69.4       16                     0                                                                                      PR                   0                               9
                                               Breast: liver metastasis               14.6       16                     0                                                                                      PR                   0                               9
  14        M        56            Bone        Lung: bone metastasis                  78.8       16                     0                                  PR                                                  NC                   0                               7
  15        M        72            Lung        NSCLC: primary tumor                   43.3       26                     0                                  CR                                                  CR                   0                               7
  16        M        67            Liver       Nasopharynx: liver metastases          111.8      26                     0                                  PR                                                  NC                   1                               5
                                               Nasopharynx: liver metastases          52.6       26                     0                                  PR                                                  NC                   0                               7
  17        F        86            Advanced    Colon: abdominal nodal metastasis      95.6       16                     0                                  CR                                                  NC                   0                               7
  18        M        80            Bone        Prostate: bone metastasis              202.4      16                     0                                                                                      PR                   0                               4
  19        F        67            Advanced    Cervix: single nodal metastasis        15         18                     0                                  PR                                                  PR                   0                               5
  20        F        49            Liver       Colon: liver metastasis                26.8       26                     0                                                                                      CR                   0                               4

choline-PET response. PTV, planning target volume; CTCAE, Common Toxicity Criteria for Adverse Events; PET, positron emission tomography; CT, computed tomography; MRI, magnetic resonance imaging; NSCLC, non-small cell lung cancer; CR, complete response; PR, partial response; NC, no change.
